New User:
-or-
Username:
Password:
Forgot your password?
News Breaks
12:53 EDTYMI
theflyonthewall.com: YM Biosciences announces Nimotuzumab results
YM BioSciences announced that results from a study evaluating nimotuzumab were presented today in a poster at the 2009 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics conference in Boston, Massachusetts. The reported results demonstrate that nimotuzumab in combination with metronomic chemotherapy in an advanced triple-negative breast cancer preclinical model is safe and effective.In this study nimotuzumab, an epidermal growth factor receptor, or EGFR, targeting antibody, was administered twice weekly in combination with metronomic cyclophosphamide. This regimen resulted in significant primary tumor growth delay in an aggressive, metastatic, higher EGFR-expressing variant of the MDA-MB-231 human breast cancer breast model, which over-expresses EGFR. In addition, the combination resulted in a significant survival advantage over cyclophosphamide alone. :theflyonthewall.com



News For YMI From The Last 14 Days
Check below for free stories on YMI the last two weeks.
There are 3 items on the Fly with pertinent information.
Sign up for a free trial to see the rest of the stories you've been missing.
February 8, 2010
17:04 EDTYMI
theflyonthewall.com: YM Biosciences reports Q2 EPS (6c) vs. consensus of (6c)
Reports Q2 revenue C$710.75K vs. consensus of $800K. (One analyst estimate). :theflyonthewall.com

February 1, 2010
07:35 EDTYMI
theflyonthewall.com: YM BioSciences completes merger with Cytopia
YM BioSciences Inc. announced that the merger of Cytopia Limited, the Australian biopharmaceutical company, into YM under a Scheme of Arrangement, has been concluded. "With the completion of this transaction, our pipeline has been expanded to incorporate Cytopia's two lead clinical candidates, CYT387 and CYT997 and its impressive pre-clinical library," said David Allan, Chairman & CEO of YM BioSciences Inc. Under the terms of the merger transaction, YM has issued 7,276,688 YM shares to former Cytopia shareholders as consideration for all of the issued and outstanding Cytopia shares. YM is also pleased to announce that Mr. Robert G.C. Watson, former Chairman of Cytopia, has been appointed to YM's Board of Directors. :theflyonthewall.com

January 26, 2010
07:34 EDTYMI
theflyonthewall.com: YM Biosciences announces FDA clearance for two Phase II nimotuzumab trials

Subscribe for More Information :theflyonthewall.com